| Jeffrey Matherne, MD | |
|
501 Morris St, Charleston, WV 25301-1326 | |
| (304) 388-6004 | |
| (304) 388-3360 |
| Full Name | Jeffrey Matherne |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 501 Morris St, Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851822035 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 35.137051 (Ohio) | Secondary |
| 207P00000X | Emergency Medicine | 29757 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Charleston Area Medical Center | Charleston, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Charleston Area Medical Center Inc | 3375441637 | 675 |
News Archive
Combination treatment using the monoclonal antibody cetuximab, along with high dose radiotherapy in the treatment of patients with loco-regionally advanced squamous cell carcinoma of the head and neck results in significant improvements in both loco-regional control and overall survival, according to Dr Jordi Giralt of Val d'Hebron University Hospital.
Outcome Sciences, Inc. (OUTCOME), the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that the Agency for Healthcare Research and Quality (AHRQ) has selected Outcome as the DEcIDE Center for a study designed to compare the effectiveness of medications versus surgery for the treatment of open-angle glaucoma. The study will enroll 2,600 patients from 30 sites across the United States and is intended to provide new scientific information about the effects of different treatment approaches in individuals who have glaucoma.
Improving productivity by keeping employees healthy and working is emerging as the top business objective for employer-sponsored wellness programs around the world. The two exceptions are the United States, where reducing health care cost increases overwhelmingly continues to be the top goal, and Asia, where the most important objective is improving workforce morale.
Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
› Verified 5 days ago
| Entity Name | Charleston Area Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124248752 PECOS PAC ID: 3375441637 Enrollment ID: O20031223000426 |
News Archive
Combination treatment using the monoclonal antibody cetuximab, along with high dose radiotherapy in the treatment of patients with loco-regionally advanced squamous cell carcinoma of the head and neck results in significant improvements in both loco-regional control and overall survival, according to Dr Jordi Giralt of Val d'Hebron University Hospital.
Outcome Sciences, Inc. (OUTCOME), the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that the Agency for Healthcare Research and Quality (AHRQ) has selected Outcome as the DEcIDE Center for a study designed to compare the effectiveness of medications versus surgery for the treatment of open-angle glaucoma. The study will enroll 2,600 patients from 30 sites across the United States and is intended to provide new scientific information about the effects of different treatment approaches in individuals who have glaucoma.
Improving productivity by keeping employees healthy and working is emerging as the top business objective for employer-sponsored wellness programs around the world. The two exceptions are the United States, where reducing health care cost increases overwhelmingly continues to be the top goal, and Asia, where the most important objective is improving workforce morale.
Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Matherne, MD 1400 Hospital Dr, Hurricane, WV 25526-9202 Ph: (304) 757-1700 | Jeffrey Matherne, MD 501 Morris St, Charleston, WV 25301-1326 Ph: (304) 388-6004 |
News Archive
Combination treatment using the monoclonal antibody cetuximab, along with high dose radiotherapy in the treatment of patients with loco-regionally advanced squamous cell carcinoma of the head and neck results in significant improvements in both loco-regional control and overall survival, according to Dr Jordi Giralt of Val d'Hebron University Hospital.
Outcome Sciences, Inc. (OUTCOME), the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that the Agency for Healthcare Research and Quality (AHRQ) has selected Outcome as the DEcIDE Center for a study designed to compare the effectiveness of medications versus surgery for the treatment of open-angle glaucoma. The study will enroll 2,600 patients from 30 sites across the United States and is intended to provide new scientific information about the effects of different treatment approaches in individuals who have glaucoma.
Improving productivity by keeping employees healthy and working is emerging as the top business objective for employer-sponsored wellness programs around the world. The two exceptions are the United States, where reducing health care cost increases overwhelmingly continues to be the top goal, and Asia, where the most important objective is improving workforce morale.
Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
› Verified 5 days ago
Barry Michael Mitchell, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 419 Brooks St, Charleston, WV 25301 Phone: 304-395-0401 | |
Adam Thomas Crawford, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3110 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-7170 Fax: 304-388-4621 | |
Dr. Hunter Nielsen, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 501 Morris St, Charleston, WV 25301 Phone: 304-388-5432 Fax: 304-388-3360 | |
Lauren B Wright, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3200 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-4172 Fax: 304-388-4155 | |
Bradley Nine, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3200 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-5432 | |
Calvin Huan Yang, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Maccorkle Ave Se, Charleston, WV 25304 Phone: 304-388-4172 Fax: 304-388-4155 | |
Roger Taylor, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 501 Morris St, Charleston, WV 25301 Phone: 304-647-6006 |